

**Amendments to the Claims.**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) An ~~optical-imaging contrast agent~~ **of formula I:**

V-L-R, (I)

**wherein:**

**V is one or more vector moieties with affinity for an abnormally expressed biological target associated with prostate cancer that target COX-2, urokinase receptor, epidermal growth factor receptor or vascular endothelial growth factor receptor (VEGFR);**

**L is a linker moiety or a bond; and**

**R is a reporter moiety comprising a cyanine dye.**

2. (Currently amended) ~~The A-contrast-agent~~ as claimed in claim 1, wherein the molecular weight **of the agent** is below 14 000 Daltons.

3. (Canceled).

4. (Canceled).

5. (Canceled).

6. (Currently amended) ~~The A-contrast-agent~~ as claimed in claim 1,3 wherein V **comprises is** ~~selected from~~ peptides, peptoid moieties, oligonucleotides, oligosaccharides, fat-related compounds and **or** traditional organic drug-like small molecules.

7. (Canceled).

8. (Currently amended) A pharmaceutical composition ~~for optical imaging of prostate cancer,~~  
comprising the ~~a~~-contrast agent as defined in claim 1, together with at least one  
pharmaceutically acceptable carrier or excipient.

9. (Canceled).

10. (Canceled).

11. (Canceled).

12. (Canceled).

13. (Canceled).